Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Nov 09, 2022 11:57am
135 Views
Post# 35085552

RE:RE:RE:Healthy movements..

RE:RE:RE:Healthy movements..
Hello and I agree that this Friday data and the KOL will be most significant for retail and the institutions. As for Roche, they already have the updated information and I believe personally that something is already going on behind the scenes whether it be partnering or buyout possibillities. They now have another 3 months of data to work with since the july 28th data cutoff for the original abstract submission and if there is a continutation or follow through of the results that we expect then we could indeed be the next and new standard of care for Panc. Tryiing to keep things level headed but hard not to get excited over it all. Big thing is how many  patients are still alive and durability for the partial responses will tell the big tale. Maybe thiese questions can be asked and answered at the KOL meeting.
<< Previous
Bullboard Posts
Next >>